US2011300215A1PendingUtilityA1

Tablet formulation of ezatiostat

40
Individually held — no corporate assignee on recordPriority: Jun 7, 2010Filed: Mar 29, 2011Published: Dec 8, 2011
Est. expiryJun 7, 2030(~3.9 yrs left)· nominal 20-yr term from priority
Inventors:Robert T. LumStephan D. ParentChunsheng QiaoSteven R. Schow
A61P 7/00A61K 31/165A61P 35/02A61K 31/216A61P 35/00A61K 9/2054C07K 5/0215A61K 9/2018A61K 9/2027
40
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed herein are tablets comprising ezatiostat hydrochloride wherein the ezatiostat hydrochloride comprises from about 75 to about 82 percent by weight of the tablet.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutically acceptable tablet comprising ezatiostat hydrochloride, an intragranular excipient, and an extragranular excipient, wherein the ezatiostat hydrochloride comprises from about 75 to about 82 percent by weight of the tablet. 
     
     
         2 . The pharmaceutically acceptable tablet of  claim 1 , wherein the ezatiostat hydrochloride comprises crystalline form D. 
     
     
         3 . The pharmaceutically acceptable tablet of  claim 1 , wherein said tablet comprises from about 100 mg to about 1250 mg of ezatiostat hydrochloride. 
     
     
         4 . The pharmaceutically acceptable tablet of  claim 1 , wherein the intragranular excipient is selected from the group consisting of mannitol, croscarmellose sodium, and hypromellose. 
     
     
         5 . The pharmaceutically acceptable tablet of  claim 4 , wherein the intragranular excipient comprises a mixture of mannitol, croscarmellose sodium, and hypromellose. 
     
     
         6 . The pharmaceutically acceptable tablet of  claim 5 , wherein the intragranular excipient comprises from about 17 to about 21 percent by weight of the tablet. 
     
     
         7 . The pharmaceutically acceptable tablet of  claim 6 , wherein total amount of the intragranular excipient is from about 19 to about 20 percent by weight of the tablet. 
     
     
         8 . The pharmaceutically acceptable tablet of  claim 7 , wherein the amount of mannitol employed in the intragranular excipient mixture ranges from about 13 to about 15 percent by weight of the tablet. 
     
     
         9 . The pharmaceutically acceptable tablet of  claim 7 , wherein the amount of croscarmellose sodium employed in the intragranular excipient mixture ranges from about 1.5 to about 3.5 percent by weight of the tablet. 
     
     
         10 . The pharmaceutically acceptable tablet of  claim 7 , wherein the amount of hypromellose employed in the intragranular excipient mixture ranges from about 2 to about 4 percent by weight of the tablet. 
     
     
         11 . The pharmaceutically acceptable tablet of  claim 1 , wherein the amount of mannitol employed in the intragranular excipient mixture is from about 13.5 to about 14.5 percent by weight of the tablet, the amount of croscarmellose sodium employed in the intragranular excipient mixture is from about 2 to about 3 percent by weight of the tablet, and the amount of hypromellose employed in the intragranular excipient mixture is from about 2.5 to about 3.5 percent by weight of the tablet. 
     
     
         12 . The pharmaceutically acceptable table of  claim 1 , wherein the extragranular excipient is selected from one or more of croscarmellose sodium and magnesium stearate. 
     
     
         13 . The pharmaceutically acceptable tablet of  claim 12 , wherein the amount of croscarmellose sodium employed in the extragranular excipient mixture is from about 1.5 to about 3.5 percent by weight of the tablet. 
     
     
         14 . The pharmaceutically acceptable tablet of  claim 12 , wherein the amount of magnesium stearate employed in the extragranular excipient mixture is from about 0.5 to about 1.5 percent by weight of the tablet. 
     
     
         15 . The pharmaceutically acceptable tablet of  claim 12 , wherein the amount of croscarmellose sodium employed in the extragranular excipient mixture is from about 2 to about 3 percent by weight of the tablet and the amount of magnesium stearate is about 1 percent by weight of the tablet. 
     
     
         16 . The pharmaceutically acceptable tablet of  claim 1 , wherein the amount of mannitol employed in the intragranular excipient mixture is from about 13.5 to about 14.5 percent by weight of the tablet, the amount of croscarmellose sodium employed in the intragranular excipient mixture is from about 2 to about 3 percent by weight of the tablet, and the amount of hypromellose employed in the intragranular excipient mixture is from about 2.5 to about 3.5 percent by weight of the tablet; and
 further wherein the amount of croscarmellose sodium employed in the extragranular excipient mixture ranges from about 2 to about 3 percent by weight of the tablet and the amount of magnesium stearate employed in the extragranular mixture is about 1 percent by weight of the tablet.   
     
     
         17 . The pharmaceutically acceptable tablet according to  claim 1 , wherein said tablet further comprises a film coating. 
     
     
         18 . The pharmaceutically acceptable tablet according to  claim 1 , wherein said tablet comprises about 500 mg of ezatiostat hydrochloride. 
     
     
         19 . The pharmaceutically acceptable tablet according to  claim 1 , wherein said tablet comprises about 750 mg of ezatiostat hydrochloride. 
     
     
         20 . The pharmaceutically acceptable tablet according to  claim 1 , wherein said tablet comprises about 1 g of ezatiostat hydrochloride. 
     
     
         21 . The pharmaceutically acceptable tablet according to  claim 1 , wherein said tablet comprises about 1.25 g of ezatiostat hydrochloride. 
     
     
         22 . The pharmaceutically acceptable table according to  claim 1 , wherein said tablet is stored in a container with a desiccant.

Join the waitlist — get patent alerts

Track US2011300215A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.